Ira Finegold, MD
Allergy · White Plains, NYNPI 1902982085
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,323 of the $16,554 with a category attached, or 86.5%. It is spread thinly across 33 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations.
Across 663 payments — averaging $24.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$3K
- Genentech USA, Inc.$2K
- Sanofi$2K
- Novartis$920
- Blueprint Medicines Corporation$677
- plus $4K from 27 others
Across 4 payments — averaging $2956.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$12K
What the payments were for
- Consulting fees$2,12513%
- Food & beverage$14,32387%
- Education$1061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 169 | $3,711 |
| GSK | 189 | $3,247 |
| Genentech USA, Inc. | 22 | $2,345 |
| Sanofi | 57 | $1,800 |
| Novartis | 49 | $920 |
| Blueprint Medicines Corporation | 16 | $677 |
| Regeneron Healthcare Solutions, Inc. | 17 | $515 |
| Amgen | 20 | $477 |
| Greer Laboratories, Inc. | 12 | $391 |
| Alk-abello, Inc | 15 | $267 |
| Teva Pharmaceuticals USA, Inc. | 9 | $238 |
| Kaleo, Inc. | 12 | $230 |
| Optinose US, Inc. | 10 | $211 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $206 |
| Covis Pharma GmbH | 9 | $201 |
| Sanofi-aventis U.S. LLC | 5 | $179 |
| Pfizer | 7 | $172 |
| Mylan Specialty L.p. | 7 | $148 |
| LEO Pharma Inc. | 5 | $98 |
| Aimmune Therapeutics, Inc. | 3 | $60 |
| Pharming Healthcare, Inc. | 2 | $57 |
| Boehringer Ingelheim | 2 | $53 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $45 |
| Incyte Corporation | 3 | $44 |
| Abbott | 2 | $41 |
| Grifols USA, LLC | 2 | $36 |
| AbbVie | 2 | $34 |
| Biocryst US Sales Co., LLC | 2 | $31 |
| CSL Behring | 1 | $29 |
| Organon | 1 | $27 |
| USWM, LLC | 1 | $27 |
| Lilly USA, LLC | 1 | $19 |
| Galderma Laboratories, L.p. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,554 in reported general payments places this provider in the 80th percentile of 92 allergy providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $29,022 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $11,495 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $6,735 |
| QnaslBeclomethasone Dipropionate | 18 | $5,470 |
| Epinephrine | 11 | $1,946 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 15 | $1,262 |
| Famotidine | 25 | $465 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $451 |
| Ipratropium Bromide | 22 | $339 |
| Montelukast Sodium | 43 | $214 |
| Levocetirizine Dihydrochloride | 15 | $207 |
| Fluticasone Propionate | 19 | $171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $3,247 | $29,02229 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,711 | $18,23036 claims |
| Teva Pharmaceuticals USA, Inc.Qnasl | $238 | $5,47018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 92 allergy providers in New York.
Other allergy in White Plains
- Noreen LinnWhite Plains$11K
- Marc BraunsteinHewlett$884K
- Allison RamseyRochester$643K
- Christopher SmithHorseheads$622K
- Anne MaitlandTarrytown$292K
- Yudhistira PersaudBronx$127K
- Michael KatlanAlbany$91K
- Michel AklJamestown$90K
- Juan SotomayorNorth Syracuse$64K
- Alan KaufmanMount Vernon$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.